| Identification | Back Directory | [Name]
H-TYR-D-ALA-GLY-PHE-MET-NH2 | [CAS]
61090-95-7 | [Synonyms]
Dalamid
TYR-D-ALA-GLY-PHE-MET-NH2
ala(2)-enkephalinamide-me
D-ALA2-MET-ENKEPHALINAMIDE
H-TYR-D-ALA-GLY-PHE-MET-NH2
enkephalinamide-Met, Ala(2)-
[D-ALA2,MET5]-ENKEPHALINAMIDE
2-D-Ala-5-Met-Enkaphalinamide
L-Tyr-D-Ala-Gly-L-Phe-L-Met-NH2
ENKEPHALINAMIDE, [D-ALA2, MET5]
ENKEPHALIN, MET- (D-ALA2; AMIDE)
TYR-D-ALA-GLY-PHE-MET-NH2 ACOH H2O
D-ALA-2-METHIONINE ENKEPHALINAMIDE)
D-alanine,methionine2 enkephalinamide
2-D-Alanine-methionine enkephalinamide
[D-ALA2,MET5]-ENKEPHALINAMIDE ACOH H2O
L-Methioninamide, L-tyrosyl-D-alanylglycyl-L-phenylalanyl- | [Molecular Formula]
C28H38N6O6S | [MDL Number]
MFCD00076418 | [MOL File]
61090-95-7.mol | [Molecular Weight]
586.7 |
| Hazard Information | Back Directory | [Uses]
[D-Ala2]-Met-Enkephalinamide, an opioid peptide, is a potent opioid agonist. [D-Ala2]-Met-Enkephalinamide decreases bile flow by a central mechanism. [D-Ala2]-Met-Enkephalinamide has analgesic properties[1][2]. | [in vivo]
[D-Ala2]-Met-Enkephalinamide decreases bile flow by a central mechanism in Sprague-Dawley rats[1]. | Animal Model: | Male Sprague-Dawley rats (250-320 g)[1] | | Dosage: | 10, 50, 100, 150, and 200 mg/kg | | Administration: | Intracerebroventrical injection | | Result: | Decreased in bile flow that ranged from 12% to 41%.
Decreased bicarbonate secretion into bile.
|
| [References]
[1] Bergasa NV, et, al. The opioid peptide analog D-Ala2-Met-enkephalinamide decreases bile flow by a central mechanism. Peptides. 1999;20(8):979-86. DOI:10.1016/s0196-9781(99)00091-1
[2] PERT CB, et, al. [D-Ala2]-Met-Enkephalinamide: A Potent, Long-Lasting Synthetic Pentapeptide Analgesic. 1976 Oct 15;194(4262):330-2. |
|
|